EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Clinical Outcomes and Cost-Effectiveness of Collaborative Dementia Care

Bernhard Michalowsky, Iris Blotenberg, Moritz Platen, Stefan Teipel, Ingo Kilimann, Elena Portacolone, Jens Bohlken, Anika Rädke, Maresa Buchholz, Annelie Scharf, Franka Muehlichen, Feng Xie und 2 weitere

JAMA Network Open · 05.07.2024 · 7 (7) · e2419282

DOI: 10.1001/jamanetworkopen.2024.19282 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 05.07.2024. Verfasst von Bernhard Michalowsky und 13 weiteren Autor:innen. Beteiligte Einrichtung: German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, Germany. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Dementia, Quality of Life. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Long-term evidence for the effectiveness and cost-effectiveness of collaborative dementia care management (CDCM) is lacking.

Objective

To evaluate whether 6 months of CDCM is associated with improved patient clinical outcomes and caregiver burden and is cost-effective compared with usual care over 36 months. Design, Setting, and Participants This was a prespecified secondary analysis of a general practitioner (GP)–based, cluster randomized, 2-arm clinical trial conducted in Germany from January 1, 2012, to December 31, 2014, with follow-up until March 31, 2018. Participants were aged 70 years or older, lived at home, and screened positive for dementia. Data were analyzed from March 2011 to March 2018.

Intervention

The intervention group received CDCM, comprising a comprehensive needs assessment and individualized interventions by nurses specifically qualified for dementia care collaborating with GPs and health care stakeholders over 6 months. The control group received usual care. Main Outcomes and Measures Main outcomes were neuropsychiatric symptoms (Neuropsychiatric Inventory [NPI]), caregiver burden (Berlin Inventory of Caregivers’ Burden in Dementia [BIZA-D]), health-related quality of life (HRQOL, measured by the Quality of Life in Alzheimer Disease scale and 12-Item Short-Form Health Survey [SF-12]), antidementia drug treatment, potentially inappropriate medication, and cost-effectiveness (incremental cost per quality-adjusted life year [QALY]) over 36 months. Outcomes between groups were compared using multivariate regression models adjusted for baseline scores.

Results

A total of 308 patients, of whom 221 (71.8%) received CDCM (mean [SD] age, 80.1 [5.3] years; 142 [64.3%] women) and 87 (28.2%) received usual care (mean [SD] age, 79.2 [4.5] years; 50 [57.5%] women), were included in the clinical effectiveness analyses, and 428 (303 [70.8%] CDCM, 125 [29.2%] usual care) were included in the cost-effectiveness analysis (which included 120 patients who had died). Participants receiving CDCM showed significantly fewer behavioral and psychological symptoms (adjusted mean difference [AMD] in NPI score, −10.26 [95% CI, −16.95 to −3.58]; P = .003; Cohen d , −0.78 [95% CI, −1.09 to −0.46]), better mental health (AMD in SF-12 Mental Component Summary score, 2.26 [95% CI, 0.31-4.21]; P = .02; Cohen d , 0.26 [95% CI, −0.11 to 0.51]), and lower caregiver burden (AMD in BIZA-D score, −0.59 [95% CI, −0.81 to −0.37]; P < .001; Cohen d , −0.71 [95% CI, −1.03 to −0.40]). There was no difference between the CDCM group and usual care group in use of antidementia drugs (adjusted odds ratio, 1.91 [95% CI, 0.96-3.77]; P = .07; Cramér V , 0.12) after 36 months. There was no association with overall HRQOL, physical health, or use of potentially inappropriate medication. The CDCM group gained QALYs (0.137 [95% CI, 0.000 to 0.274]; P = .049; Cohen d , 0.20 [95% CI, −0.09 to 0.40]) but had no significant increase in costs (437€ [−5438€ to 6313€] [US $476 (95% CI, −$5927 to $6881)]; P = .87; Cohen d , 0.07 [95% CI, −0.14 to 0.28]), resulting in a cost-effectiveness ratio of 3186€ (US $3472) per QALY. Cost-effectiveness was significantly better for patients living alone (CDCM dominated, with lower costs and more QALYs gained) than for those living with a caregiver (47 538€ [US $51 816] per QALY). Conclusions and Relevance In this secondary analysis of a cluster randomized clinical trial, CDCM was associated with improved patient, caregiver, and health system–relevant outcomes over 36 months beyond the intervention period. Therefore, it should become a health policy priority to initiate translation of CDCM into routine care. Trial Registration ClinicalTrials.gov Identifier: NCT01401582

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisDementiaQuality of LifeHumansFemaleMaleAgedAged, 80 and overCaregiversGermanyCaregiver BurdenQuality-Adjusted Life Years

Autor:innen und Institutionen

  • German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Rostock, Germany.
  • Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.
  • Institute for Health & Aging, University of California, San Francisco.
  • Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
  • Institute of Social Medicine, Occupational Health and Public Health, Faculty of Medicine, University of Leipzig, Leipzig, Germany.

Zitieren

APA

Michalowsky, B., Blotenberg, I., Platen, M., Teipel, S., Kilimann, I., Portacolone, E., Bohlken, J., Rädke, A., Buchholz, M., Scharf, A., Muehlichen, F., Xie, F., Thyrian, J. R., & Hoffmann, W. (2024). Clinical Outcomes and Cost-Effectiveness of Collaborative Dementia Care. JAMA Network Open, 7(7), e2419282. https://doi.org/10.1001/jamanetworkopen.2024.19282

Vancouver

Michalowsky B, Blotenberg I, Platen M, Teipel S, Kilimann I, Portacolone E, et al. Clinical Outcomes and Cost-Effectiveness of Collaborative Dementia Care. JAMA Network Open. 2024;7(7):e2419282. doi:10.1001/jamanetworkopen.2024.19282

BibTeX
@article{Michalowsky2024,
  author = {Michalowsky, Bernhard and Blotenberg, Iris and Platen, Moritz and Teipel, Stefan and Kilimann, Ingo and Portacolone, Elena and Bohlken, Jens and Rädke, Anika and Buchholz, Maresa and Scharf, Annelie and Muehlichen, Franka and Xie, Feng and Thyrian, Jochen René and Hoffmann, Wolfgang},
  title = {Clinical Outcomes and Cost-Effectiveness of Collaborative Dementia Care},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {7},
  pages = {e2419282},
  doi = {10.1001/jamanetworkopen.2024.19282}
}
Kostenlos starten →